© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Seer, Inc. (SEER) stock declined over -0.61%, trading at $1.62 on NASDAQ, down from the previous close of $1.63. The stock opened at $1.65, fluctuating between $1.55 and $1.65 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 02, 2026 | 1.61 | 1.65 | 1.55 | 1.62 | 5.71M |
| Jul 01, 2026 | 1.70 | 1.72 | 1.63 | 1.63 | 522.26K |
| Jun 30, 2026 | 1.67 | 1.70 | 1.66 | 1.66 | 169.09K |
| Jun 29, 2026 | 1.68 | 1.70 | 1.66 | 1.66 | 218.18K |
| Jun 26, 2026 | 1.72 | 1.76 | 1.66 | 1.66 | 438.86K |
| Jun 25, 2026 | 1.71 | 1.74 | 1.70 | 1.73 | 90.11K |
| Jun 24, 2026 | 1.72 | 1.76 | 1.69 | 1.69 | 118.09K |
| Jun 23, 2026 | 1.76 | 1.78 | 1.72 | 1.73 | 115.27K |
| Jun 22, 2026 | 1.73 | 1.77 | 1.72 | 1.76 | 161.42K |
| Jun 18, 2026 | 1.72 | 1.74 | 1.71 | 1.74 | 102.1K |
| Jun 17, 2026 | 1.71 | 1.74 | 1.71 | 1.72 | 64.91K |
| Jun 16, 2026 | 1.70 | 1.74 | 1.70 | 1.71 | 141.5K |
| Jun 15, 2026 | 1.75 | 1.77 | 1.71 | 1.71 | 106.69K |
| Jun 12, 2026 | 1.70 | 1.73 | 1.69 | 1.72 | 96.25K |
| Jun 11, 2026 | 1.72 | 1.72 | 1.68 | 1.70 | 155.53K |
| Jun 10, 2026 | 1.67 | 1.74 | 1.67 | 1.69 | 78.67K |
| Jun 09, 2026 | 1.79 | 1.79 | 1.69 | 1.69 | 436.66K |
| Jun 08, 2026 | 1.79 | 1.81 | 1.78 | 1.79 | 171K |
| Jun 05, 2026 | 1.85 | 1.85 | 1.78 | 1.79 | 76.28K |
| Jun 04, 2026 | 1.86 | 1.87 | 1.84 | 1.85 | 45.12K |
Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.
| Employees | 134 |
| Beta | 1.59 |
| Sales or Revenue | $15.18M |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |